134,089 Shares in Maravai LifeSciences Holdings, Inc. $MRVI Acquired by Voleon Capital Management LP

Key Points

• Voleon Capital Management LP has acquired a new position in Maravai LifeSciences, investing approximately $296,000 to purchase 134,089 shares of the company.
• Analysts have revised their price targets for Maravai LifeSciences, with the consensus rating currently at "Hold" and an average target price of $5.22.
• Maravai LifeSciences has a market capitalization of $679.26 million, with shares opening at $2.66, indicating a 12-month low of $1.66 and a high of $9.50.

Voleon Capital Management LP purchased a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 134,089 shares of the company's stock, valued at approximately $296,000. Voleon Capital Management LP owned approximately 0.05% of Maravai LifeSciences at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Sherbrooke Park Advisers LLC purchased a new position in Maravai LifeSciences during the fourth quarter worth approximately $78,000. EntryPoint Capital LLC purchased a new position in Maravai LifeSciences during the first quarter worth approximately $32,000. Teacher Retirement System of Texas purchased a new position in Maravai LifeSciences during the first quarter worth approximately $37,000. Aigen Investment Management LP purchased a new position in Maravai LifeSciences during the first quarter worth approximately $37,000. Finally, Performa Ltd US LLC boosted its position in Maravai LifeSciences by 245.0% during the first quarter. Performa Ltd US LLC now owns 17,250 shares of the company's stock worth $38,000 after purchasing an additional 12,250 shares in the last quarter. Hedge funds and other institutional investors own 50.25% of the company's stock.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada reduced their target price on Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a report on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $5.22.

Maravai LifeSciences Price Performance

Shares of NASDAQ:MRVI remained flat at $2.67 during midday trading on Monday. The company had a trading volume of 450,132 shares, compared to its average volume of 2,275,053. The firm's fifty day moving average is $2.49 and its 200-day moving average is $2.32. The company has a current ratio of 5.16, a quick ratio of 4.49 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $681.81 million, a PE ratio of -1.96 and a beta of 0.29. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.66 and a 12-month high of $9.50.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.